Scaling Vision Innovation
Rob Scott, Vice President of Intraocular Devices R&D, Alcon
Clinical Scorecard: Scaling Vision Innovation
At a Glance
| Category | Detail |
|---|
| Condition | Presbyopia and cataracts |
| Key Mechanisms | Advancements in implantable technologies, particularly presbyopia-correcting intraocular lenses (PCIOLs) |
| Target Population | Individuals with moderate-to-severe uncorrected refractive errors, presbyopia, and cataracts |
| Care Setting | Ophthalmology clinics and surgical centers |
Key Highlights
- 157 million people globally have moderate-to-severe uncorrected refractive errors
- Alcon's PanOptix Pro IOL recovers 50% of light previously lost to scatter
- Over six million Alcon PCIOLs implanted globally
- Cataract surgeries expected to reach 100 million annually by 2050
- Innovation in ophthalmology must balance visual benefits and trade-offs
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and refractive errors in patients
- Evaluate the presence of cataracts and their impact on vision
Management
- Utilize advanced PCIOLs for presbyopia and cataract treatment
- Incorporate surgeon feedback into product development and improvements
Monitoring & Follow-up
- Regular follow-up on patient outcomes post-IOL implantation
- Monitor advancements in technology and their clinical implications
Risks
- Potential complications from rapid PCIOL innovation
- Balancing visual benefits with safety in new designs
Patient & Prescribing Data
Patients undergoing cataract surgery or seeking correction for presbyopia
Focus on personalized IOL selection based on individual patient needs and feedback from eye care professionals
Clinical Best Practices
- Engage with eye care professionals to inform R&D decisions
- Prioritize innovations that enhance patient outcomes and safety
- Adopt data-driven approaches for IOL selection and diagnostics
References
